Luke Hipperson

Mar 4, 2024 | onlinelibrary.wiley.com | Sooin Byeon |Taymin du Toit-Thompson |Luke Hipperson |Sarah Maloney

1 INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and has one of the worst prognostic outcomes (~9% 5-year survival) among all major solid tumors.1 In fact, it is projected to become the second leading cause of cancer-related deaths by 2030.2 The late-stage diagnosis of PDAC is attributable to dismal survival outcomes, as a majority of patients have advanced, unresectable disease at diagnosis.